Powered by

Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company

Jan 17, 2019 - Business Wire

Ablexis, LLC , a biopharmaceutical company focused on licensing its AlivaMab Mouse platform technology for antibody drug discovery, today announced the expansion of its existing non-exclusive perpetual license agreement with Eli Lilly and Company. The expanded rights will more broadly enable EIi Lilly to use the AlivaMab Mouse platform for projects with collaborators, including the right to grant sub-licenses to antibody drug candidates much earlier in discovery. Financial terms of the agreement...